Latisse

The LATISSE™ Wishes Campaign

The LATISSE™ Wishes campaign was borne out of the tradition of blowing on an eyelash to make a wish come true and leverages the excitement surrounding the availability of Allergan’s LATISSE™ (bimatoprost ophthalmic solution) 0.03%, the first and only science-based prescription treatment approved by the U.S. Food and Drug Administration and indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, fullness and darkness. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE™ Wishes kicked off March 26 with a star-studded Hollywood event with campaign ambassadors and LATISSE™ users, Brooke and Anastasia.

 

Support the LATISSE™ Wishes Campaign to Help Grant Wishes

LATISSE™ Wishes launched with an initial donation of $500,000 from Allergan to the Make-A-Wish Foundation. Consumers are encouraged to help double this amount to $1 million by registering their support at www.LATISSE.com to help grant the wishes of children in their local communities. Between now and December 31, 2009, Allergan will donate $5 for each new visitor who registers online, up to an additional $500,000.

Tell Your Patients about LATISSE™ and the LATISSE™ Wishes Campaign

The launch of LATISSE™ Wishes provides an opportunity for you to reach out to your patients to let them know how they can learn more about LATISSE™ while joining an important cause by registering their support for LATISSE™ Wishes and the Make-A-Wish Foundation at www.LATISSE.com. Below and attached is an announcement that you can share with your patients with more information about the campaign.

Important Safety Information

Contraindications: LATISSE™ is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.

 

Warnings and Precautions: In patients using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the concomitant use of LATISSE™ may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE™ after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when the same formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal pigmentation was not reported in clinical studies with LATISSE™, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.

There is the potential for hair growth to occur in areas where LATISSE™ solution comes in repeated contact with skin surfaces.

LATISSE™ solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

 

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.

For more information on LATISSE™, please click here or in the images below.

Latisse Product Information	Latisse Campaign Announcement	Latisse Press Release